Currently, available treatments for FD are limited and include ERT (agalsidase-α and agalsidase-β since 2001) and chaperone therapy (Galactose since 2001 [13] and migalastat [14] since 2016), and a few novel approaches which are under investigation. The gene discussed is ELF3; the disease is Fabry disease.